professor Venture Fair Judges
Matt Cohen joined Osage University Partners in 2013 and serves as senior associate. Prior to joining Osage, Cohen was a strategy consultant with L.E.K. Consulting serving clients in biopharma, diagnostics, research tools, health care, and private equity. Engagements included portfolio strategy development, market assessment, commercialization support, acquisition target identification, and diligence/transaction support. As a Ph.D. student at the University of Pennsylvania, Cohen conducted research on the antibody response to a novel protein-based poxvirus vaccine and advised several startups while working with the Penn Biotech Group. Matt holds a Ph.D. in cell and molecular biology and a B.S. in microbiology from The University of Pennsylvania.
Herbert (Herb) Heyneker received his Ph.D. in molecular genetics in 1975 from the University of Leiden in the Netherlands and conducted postdoctoral work in Herbert Boyer’s lab at the University of California, San Francisco. Next, he became one of the first scientists of Genentech, focusing on genetically expressing therapeutic proteins, including human insulin and human growth hormone. In 1984, Heyneker joined Genencor , a Genentech spinoff, as vice president of research. In the 1990s, Heyneker co-founded three biotechnology companies: Glycogen, Protogene and Eos Biotechnology. At Eos, he designed a highly parallel DNA synthesis instrument (U.S. patent 6,264,891), which was used by a wholly-owned subsidiary of Eos to sell oligos over the internet. Invitrogen later purchased the business. After Protein Design Labs acquired Eos, he joined the London-based venture capital firm Abingworth as an advisor from 2003-2010. Since 2008, he has served as an advisor for Utrecht-based Thuja Capital. In 2013, he co-founded MucoTrans, LLC with Xiaoping Zhu, professor in the Department of Veterinary Medicine at the University of Maryland. MucoTrans focuses on needle-free delivery of vaccines through the epithelial mucosa. In 2014, Zhu and Heyneker co-founded Inhalex Therapeutics, LLC. The company focuses on CD23 receptor mediated transport of anti-inflammatory proteins through the airway epithelial barrier. Heyneker currently serves as CEO of MucoTrans and Inhalex. Heyneker has authored more than 50 peer-reviewed papers and been named as an inventor on over 30 U.S. patents.
Ken Malone joined BHI in 2013 as an entrepreneur-in-residence located at University of Maryland Ventures. He has built his career on creating economic value from science. Whether it was developing new business lines for global corporations or spinning out new ventures from universities, Malone has engaged in the commercialization of hundreds of new products in advanced materials and life sciences. After a productive career with large corporations and during a stint with a research intensive university, Malone recognized the need for creative business finance and flexible business structures to convert science into economic value during its earliest stages. In 2005, he founded what is now Early Charm Ventures, LLC to address the need. Through Early Charm, Malone has provided his services to over a dozen early-stage ventures while co-founding and/or being an officer of five advanced materials and life science startups.
Rana Quraishi has spent much of her career working in life science-directed finance, investment and consulting organizations. At the TCG Group, a premiere private equity firm, she focused on business development opportunities for its life science companies. Prior to this she was a principal at Conning Capital Partners/SwissRe an early-stage private equity fund providing growth capital for entrepreneurial companies where she served on the boards of several portfolio companies. Quraishi was also CFO/senior advisor for Helicon Therapeutics, a startup with assets contributed by Cold Spring Harbor and OSI Pharmaceuticals. She developed the company's business plan and made investor presentations leading to $6 million in initial funding. Helicon was subsequently acquired. Earlier in her career, Quraishi worked for Standard and Poor’s, served as commercial quality leader at GE Capital, and headed the business development group at its FGIC subsidiary, J.E. Seagram, and American Express where she led the treasury and acquisitions and divestitures groups. She has served on several for-profit and not for-profit boards, and has also authored the widely read “Market Demand Study for Commercial Biotechnology, Biomedical, and Bioinformatics Facilities in New York City” for the New York City Partnership and Investment Fund. Quraishi has a Ph.D. in molecular biology and biochemistry and an undergraduate degree from Columbia University and an M.S. from Harvard University.